KLRK1 and neoplasm: Therefore, we expect that periodic “refreshing” of the NKG2D+ immune cells will lead to constant shrinking of the tumor mass, sustained reduction of sNKG2DL plasma levels, and extended antitumor activity of NKG2D+ immune cells.